Herman van Vlijmen; Jean-Yves Ortholand; Volkhart M-J Li; Jon SB de Vlieger
Drug Discov. Today, 2021, 26(10), 2406-2413
https://doi.org/10.1016/j.drudis.2021.04.019

Abstract

Through the European Lead Factory model, industry-standard high-throughput screening and hit validation are made available to academia, small and medium-sized enterprises, charity organizations, patient foundations, and participating pharmaceutical companies. The compound collection used for screening is built from a unique diversity of sources. It brings together compounds from companies with different therapeutic area heritages and completely new compounds from library synthesis. This generates structural diversity and combines molecules with complementary physicochemical properties. In 2019, the screening library was updated to enable another 5 years of running innovative drug discovery projects. Here, we investigate the physicochemical and diversity properties of the updated compound collection. We show that it is highly diverse, drug like, and complementary to commercial screening libraries.